Clinical trial · Observational
Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir
NCT03247296CI-TRIAL-00029033unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the early detection of HCC in patients Taking Sofosbuvir and Daclatasvir.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatitis C | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sofosbuvir 400 mg, Daclatasvir, Ribavirin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A
- description
- Patients taking Sofosbuvir and Daclatasvir
- interventionNames
- Drug: Sofosbuvir 400 mg, Daclatasvir, Ribavirin
- label
- Group B
- description
- Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
- interventionNames
- Drug: Sofosbuvir 400 mg, Daclatasvir, Ribavirin
Primary outcomes (1)
- measure
- HCC
- timeFrame
- 24 weeks
- description
- occurence of HCC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients have positive HCV-RNA and taking DAAS to treat it. * Both sexes will be included * Age above 18 to 75 years old * Child Pugh score ( A and B ) Exclusion Criteria: * Total serum bilirubin\<3 mg/dl * Serum albumin \> 2.8 g/dl * INR≥ 1.7 * Platelet count\< 50000/mm3 IF any of the above criteria is not caused by liver disease, the patient can be included in the study. * HCC, except 4 weeks after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI). * Extra- hepatic malignancy. * Pregnancy or inability to use effective contraception. * Inadequately controlled diabetes mellitus (HbA1c\>9%).
References
Publications (0)
Data not yet available
No reference posted for this study.